New York State Common Retirement Fund Has $144.81 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

New York State Common Retirement Fund cut its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,822,197 shares of the biopharmaceutical company's stock after selling 363,470 shares during the quarter. New York State Common Retirement Fund owned about 0.14% of Bristol-Myers Squibb worth $144,807,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BMY. Institute for Wealth Management LLC. raised its position in shares of Bristol-Myers Squibb by 1.0% during the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company's stock worth $1,542,000 after buying an additional 296 shares in the last quarter. Herold Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 3.2% during the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company's stock worth $1,954,000 after buying an additional 1,051 shares in the last quarter. Kestra Private Wealth Services LLC raised its position in shares of Bristol-Myers Squibb by 9.5% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company's stock worth $8,115,000 after buying an additional 12,121 shares in the last quarter. Metis Global Partners LLC raised its position in shares of Bristol-Myers Squibb by 14.8% during the 3rd quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company's stock worth $5,907,000 after buying an additional 13,122 shares in the last quarter. Finally, Jmac Enterprises LLC raised its position in shares of Bristol-Myers Squibb by 11.4% during the 3rd quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company's stock worth $706,000 after buying an additional 1,245 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 0.3 %

BMY traded down $0.15 on Tuesday, reaching $48.99. 9,146,777 shares of the company traded hands, compared to its average volume of 15,525,874. The stock's 50 day moving average price is $51.22 and its 200-day moving average price is $51.38. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The company has a market cap of $99.29 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.82 earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.90%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 62.18%.

Analyst Ratings Changes

BMY has been the topic of several recent research reports. Societe Generale cut shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. StockNews.com cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 18th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Bank of America cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.